by Phillip Maples, Padma Kumar, Ila Oxendine, Chris Jay, Yang Yu, Joseph Kuhn, and John Nemunaitis
Volume 8, Issue 1 (Spring 2009)
We have designed a novel autologous vaccine by combining two vaccine strategies that have each been previously tested in separate non-small cell lung cancer (NSCLC) clinical trials: 1) a GM-CSF gene transduced tumor cell vaccine; and 2) a TGFβ2 antisense gene transduced cell vaccine. Each has demonstrated similar beneficial effects without any evidence of significant toxicity in advanced cancer patients…
Citation:
Maples P, Kumar P, Oxendine I, Jay C, Yu Y, Kuhn J, Nemunaitis J. TAG Vaccine: Autologous Tumor Vaccine Genetically Modified to Express GM-CSF and Block Production of TGFB2. BioProcess J, 2009; 8(1): 38-44. http://dx.doi.org/10.12665/J81.Maples.P2